| Identification | Back Directory | [Name]
PF-05231023 | [CAS]
1037589-69-7 | [Synonyms]
PF5231023
PF-5231023
PF 5231023
PF-05231023
Mal-amido-PEG2-C2-amido-Ph-C2-CO-AZD
PF-05231023; PF05231023; PF 05231023; PF-5231023; PF5231023; PF 5231023
1H-Pyrrole-1-propanamide, 2,5-dihydro-2,5-dioxo-N-[2-[2-[3-oxo-3-[[4-[3-oxo-3-(2-oxo-1-azetidinyl)propyl]phenyl]amino]propoxy]ethoxy]ethyl]- | [Molecular Formula]
C26H32N4O8 | [MDL Number]
MFCD31807610 | [MOL File]
1037589-69-7.mol | [Molecular Weight]
528.55 |
| Chemical Properties | Back Directory | [Boiling point ]
849.9±65.0 °C(Predicted) | [density ]
1.345±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 30 mg/ml; DMSO: 30 mg/ml; DMSO:PBS (pH 7.2) (1:4): 0.2 mg/ml | [form ]
A solid | [pka]
14.34±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Mal-amido-PEG2-C2-amido-Ph-C2-CO-AZD (Mal-PEG2-AZD) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1]. | [in vivo]
| Animal Model: | Eight week old Zucker rats[3] | | Dosage: | 3?mg/kg and 10?mg/kg | | Administration: | Subcutaneously twice a week for two weeks | | Result: | There was no change of BW observed, and food intake was not changed in the treated groups compared to control. Caused a significant decrease of glucose excursion during the oral glucose tolerance test (OGTT) compared to control. |
| Animal Model: | 7-to-8-month-old Akita mice with type 1 diabete model[4] | | Dosage: | 10 mg/kg | | Administration: | Intraperitoneally injected; twice a week; for four weeks | | Result: | Administration improved retinal function in diabetic Akita mice. |
| [IC 50]
PEGs | [References]
[1] Sonoda J, et al. FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases. Horm Mol Biol Clin Investig. 2017 May 19;30(2). DOI:10.1515/hmbci-2017-0002 |
|
|